Robotic Radiotherapy Market Report 2024-2034: Lucrative Opportunities in Emerging Markets, Partnerships and Collaborations, & Personalized Medicine
04 mars 2025 10h21 HE
|
Research and Markets
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Robotic Radiotherapy Market by Product, by Technology, by Application, by End-user, and by Region" report has been added to ResearchAndMarkets.com's...
ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference
25 févr. 2025 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 25 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide topline data results from its Phase...
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
24 févr. 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
20 févr. 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
18 févr. 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
ITM to Present at Raymond James Private Biotech Symposium
18 févr. 2025 05h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Raymond James Private Biotech...
ITM to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
07 févr. 2025 08h00 HE
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 7, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in Oppenheimer’s 35th Annual Healthcare...
ITM Announces Positive Topline Results of Phase 3 COMPETE Trial with ITM-11, a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
28 janv. 2025 05h00 HE
|
ITM Isotope Technologies Munich SE
Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimusITM plans...
Radiosurgery and Radiotherapy Robotics Market Research 2024-2028: Global and Country-Level Insights for X-ray & Gamma-ray-based Robots by End-user
23 janv. 2025 05h01 HE
|
Research and Markets
Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Radiosurgery and Radiotherapy Robotics Market 2024-2028" report has been added to ResearchAndMarkets.com's offering.The radiosurgery and radiotherapy...
Endorectal Balloon Market to Witness Remarkable Growth, Reaching US$ 549.7 Million by 2034 at a Strong CAGR of 9.9% | Fact.MR Report
21 janv. 2025 07h30 HE
|
FACT.MR
Rockville, MD, Jan. 21, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global endorectal balloons market is estimated to reach a...